Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Infliximab for maintenance of remission in Crohn's disease

Esta versión no es la más reciente

ver la versión actual 19 febrero 2024

Información

DOI:
https://doi.org/10.1002/14651858.CD012609Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 22 marzo 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Salud digestiva

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Robert Battat

    Division of Gastroenterology, Jewish General Hospital, Montreal, Canada

    Division of Gastroenterology, McGill University Health Centre, Montreal, Canada

  • Navjot Deol

    Department of Medicine, University of Western Ontario, London, Canada

  • Tran M Nguyen

    Cochrane IBD Group, Robarts Clinical Trials, London, Canada

  • Claire E Parker

    Robarts Clinical Trials, London, Canada

  • Reena Khanna

    Department of Medicine, University of Western Ontario, London, Canada

    Robarts Clinical Trials, London, Canada

  • Brian G Feagan

    Department of Medicine, University of Western Ontario, London, Canada

    Cochrane IBD Group, Robarts Clinical Trials, London, Canada

    Robarts Clinical Trials, London, Canada

    Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada

  • Vipul Jairath

    Correspondencia a: Department of Medicine, University of Western Ontario, London, Canada

    [email protected]

    Robarts Clinical Trials, London, Canada

    Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada

Contributions of authors

All authors were involved in the development of this protocol.

Declarations of interest

Robert Battat, Navjot Deol, Tran M Nguyen and Claire E Parker have no known conflicts.

Reena Khanna has received honoraria from AbbVie, Jansen, and Takeda for consultancy. All of these activities are outside the submitted work.

Brian G Feagan has received fee(s) from Abbott/AbbVie, Amgen, Astra Zeneca, Avaxia Biologics Inc., Bristol‐Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Ferring, JnJ/Janssen, Merck, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Takeda, Teva, Tillotts Pharma AG, UCB Pharma for Board membership; fee(s) from Abbott/AbbVie, Actogenix, Albireo Pharma, Amgen, Astra Zeneca, Avaxia Biologics Inc., Axcan, Baxter Healthcare Corp., Boehringer‐Ingelheim, Bristol‐Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, GiCare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Merck, Millennium, Nektar, Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, Tillotts, UCB Pharma, Vertex Pharma, Warner‐Chilcott, Wyeth, Zealand, and Zyngenia for consultancy; and lecture fee(s) from: Abbott/AbbVie, JnJ/Janssen, Takeda, Warner‐Chilcott, and UCB Pharma. All of these activities are outside the submitted work.

Vipul Jairath has received scientific advisory board fees from Abbvie, Sandoz, Ferring and Janssen; speaker's fees from Takeda and Ferring; and travel support for conference attendance from Vifor pharmaceuticals.

Acknowledgements

Partial funding for the Cochrane IBD Group (April 1, 2016 ‐ March 31, 2018) has been provided by Crohn's and Colitis Canada (CCC).

Version history

Published

Title

Stage

Authors

Version

2024 Feb 19

Infliximab for maintenance of medically‐induced remission in Crohn's disease

Review

Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Arni Sarian, Gordon William Moran

https://doi.org/10.1002/14651858.CD012609.pub2

2017 Mar 22

Infliximab for maintenance of remission in Crohn's disease

Protocol

Robert Battat, Navjot Deol, Tran M Nguyen, Claire E Parker, Reena Khanna, Brian G Feagan, Vipul Jairath

https://doi.org/10.1002/14651858.CD012609

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.